We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exactech (EXAC) Scales a 52-Week High on Product Innovation
Read MoreHide Full Article
Shares of Exactech Inc. , renowned developer of bone and joint restoration products, rallied to a new 52-week high of $27.51 on Jul 11, closing a tad bit lower at $27.34. This represents a strong one-year return of approximately 30.49%, substantially higher than the S&P 500’s 1.79% over the same time period.
This Zacks Rank #3 (Hold) stock has a market cap of $388.35 million and an impressive long-term expected earnings growth rate of 8.90%.
Over the past one month, Exactech witnessed a couple of positive developments which drove its share price significantly. On Jun 20, Exactech announced the launch of Acapella One Cervical Spacer System, which was another milestone addition to its line of innovative products. The product will boost Exatech’s Spine service business to a large extent, fortifying its hold in the space.
In the same month, Exactech announced investment in two Arcam Q10plus devices to expand its hold in manufacturing technology. The company is confident that this investment will benefit its existing manufacturing systems.
In this regard, we note that, in a continuous bid to expand in the field of orthopedic implant devices, Exactech launched several products last year and has maintained the trend in 2016 so far. These along with its pilot launches of three revision system pertaining to hip stem and knee will drive growth in the second and third quarter of 2016.
Key Picks
Better-ranked stocks in the broad medical sector include ABIOMED, Inc. , Mesa Laboratories Inc. (MLAB - Free Report) and Masimo Corp (MASI - Free Report) All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exactech (EXAC) Scales a 52-Week High on Product Innovation
Shares of Exactech Inc. , renowned developer of bone and joint restoration products, rallied to a new 52-week high of $27.51 on Jul 11, closing a tad bit lower at $27.34. This represents a strong one-year return of approximately 30.49%, substantially higher than the S&P 500’s 1.79% over the same time period.
This Zacks Rank #3 (Hold) stock has a market cap of $388.35 million and an impressive long-term expected earnings growth rate of 8.90%.
Over the past one month, Exactech witnessed a couple of positive developments which drove its share price significantly. On Jun 20, Exactech announced the launch of Acapella One Cervical Spacer System, which was another milestone addition to its line of innovative products. The product will boost Exatech’s Spine service business to a large extent, fortifying its hold in the space.
In the same month, Exactech announced investment in two Arcam Q10plus devices to expand its hold in manufacturing technology. The company is confident that this investment will benefit its existing manufacturing systems.
EXACTECH INC Price and Consensus
EXACTECH INC Price and Consensus | EXACTECH INC Quote
In this regard, we note that, in a continuous bid to expand in the field of orthopedic implant devices, Exactech launched several products last year and has maintained the trend in 2016 so far. These along with its pilot launches of three revision system pertaining to hip stem and knee will drive growth in the second and third quarter of 2016.
Key Picks
Better-ranked stocks in the broad medical sector include ABIOMED, Inc. , Mesa Laboratories Inc. (MLAB - Free Report) and Masimo Corp (MASI - Free Report) All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>